DelMar Pharmaceuticals (NASDAQ:DMPI) has been assigned a consensus broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and three have given a strong buy rating to the company. DelMar Pharmaceuticals’ rating score has improved by 10.2% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Brokerages have set a twelve-month consensus price objective of $11.16 for the company and are expecting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 179 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright set a $12.00 price target on shares of DelMar Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, January 4th.
NASDAQ DMPI remained flat at $$0.92 during trading on Friday. 31,391 shares of the company’s stock were exchanged, compared to its average volume of 592,115. The firm has a market capitalization of $20.55, a PE ratio of -1.24 and a beta of 1.47. DelMar Pharmaceuticals has a 1 year low of $0.78 and a 1 year high of $4.45.
DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its earnings results on Thursday, February 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. equities research analysts anticipate that DelMar Pharmaceuticals will post -0.46 earnings per share for the current fiscal year.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.